GlassScriptPhysician profile
Nikhil Karanth
NPI 1144332586
$24,917.67
in general payments reported to CMS, 2019-2025
24 companies · $203 in 2025
The $203 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,457 · 2020: $85.08 · 2021: $6,152 · 2022: $4,709 · 2023: $9,934 · 2024: $379 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,000 · Food and Beverage: $1,299 · Travel and Lodging: $131 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,000.00 |
| Food and Beverage | $1,298.99 |
| Travel and Lodging | $131.26 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $14,694.68 | 2020-2025 | |
| Ironwood Pharmaceuticals, INC | $4,900.00 | 2020-2024 | Linzess |
| Allergan, INC. | $3,355.84 | 2019 | |
| Celgene Corporation | $294.17 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $275.20 | 2022-2024 | Stelara, Remicade, Simponi |
| Cook Medical LLC | $175.03 | 2022 | |
| Daiichi Sankyo INC. | $155.90 | 2022 | |
| Redhill Biopharma INC. | $146.70 | 2021-2023 | Talicia, Movantik, Aemcolo |
| Janssen Scientific Affairs, LLC | $138.18 | 2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $100.68 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.55 | 2020-2023 | Xifaxan |
| Ardelyx, INC. | $90.17 | 2022-2023 | Ibsrela |
| Merck Sharp & Dohme LLC | $78.76 | 2021-2023 | |
| Qol Medical, LLC | $69.91 | 2021 | |
| Boston Scientific Corporation | $69.10 | 2023-2025 | Watchman Flx |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $53.68 | 2022-2023 | |
| Intra-Sana Laboratories | $50.54 | 2021-2023 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Nestle Healthcare Nutrition INC. | $47.46 | 2022 | |
| Braintree Laboratories, INC. | $40.45 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $19.71 | 2021 | |
| Endogastric Solutions, INC | $17.70 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.69 | 2021 | |
| Alexion Pharmaceuticals, INC. | $15.57 | 2021 | |
| Aimmune Therapeutics, INC. | $15.00 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikhil Karanth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.